Neutra Corp's Strategic Pivot to Clinical Research Drives Projected 1,000% Revenue Growth

Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, has announced a successful strategic pivot into the clinical research industry, resulting in a projected revenue increase of more than 1,000% year-over-year. This growth is driven by the launch and rapid expansion of its wholly owned subsidiary, Neutra Life Sciences, a clinical research Site Management Organization (SMO). Neutra Life Sciences was established to address the growing demand for high-quality, compliant, and scalable clinical trial site operations. Since its formation, the subsidiary has executed multiple site partnerships, expanded its investigator network, and initiated new clinical studies across several therapeutic areas.

As part of its 2025 pivot, Neutra Life Sciences participated in Parexel's Emerging Site Scholarship Program and was selected as one of the Emerging Site Partners. This positions Neutra Life Sciences among a select group of sites receiving targeted operational support, specialized training, and enhanced access to global clinical trial opportunities. The program is designed to strengthen research capacity, improve regulatory readiness, and expand each site's ability to participate in innovative and high-impact clinical studies. Sydney Jim, President and CEO of Neutra Life Sciences, stated, "We are honored to have Neutra Life Sciences chosen by Parexel for this prestigious partnership. This collaboration validates our commitment to advancing clinical research and expanding our capabilities in life sciences. Working alongside Parexel will accelerate our growth, elevate our research infrastructure, and open doors to more trials."

Through this partnership, Neutra Life Sciences will benefit from operational mentorship and hands-on site development support, access to training and professional development for clinical staff, increased exposure to global clinical trial sponsors, and opportunities to participate in cutting-edge, high-value clinical research. Jim added, "This milestone strengthens our mission to become a leading contributor to clinical research innovation. Parexel's support will empower our team to deliver high-quality, patient-focused research while expanding the range of trials accessible to our community." The Emerging Site Partnership is expected to accelerate Neutra Life Sciences' clinical trial capabilities across multiple therapeutic areas and further solidify Neutra Corp's strategic position within the life sciences sector.

Looking ahead to 2026, Neutra Corp expects continued growth driven by the expansion of its clinical research operations. The Company plans to increase study volume across existing partnerships and deepen relationships with sponsors and CROs. Management believes the clinical research vertical will serve as a primary growth engine moving forward, providing recurring revenue and long-term scalability. For more information about the company's operations, visit https://www.neutrainc.com. Additional details about Neutra Life Sciences can be found at https://www.neutralifesciences.com, while information about their partner organization is available at https://www.parexel.com. The strategic pivot represents a significant transformation for Neutra Corp, shifting from its previous focus areas to capitalize on the growing clinical research market, which is experiencing increased demand for efficient trial execution and patient-centric approaches.